BIOMAT Database Logo BIOMAT Database Logo

Induction of anomalous killing activity from antigen-specific CTL clones by adding high doses of human recombinant interleukin 2. 1988

T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Division of Radiation Health, National Institute of Radiological Sciences, Chiba, Japan.

Four out of six long-term murine cytotoxic T lymphocyte (CTL) clones specific for trinitrophenyl (TNP)-modified spleen cells could develop an anomalous cytotoxicity against syngeneic and allogeneic tumor cells upon stimulation with TNP-modified spleen cells and high doses of human recombinant interleukin 2 (rIL-2). On FACS analysis, hyperactivated CTLs were positive for Thy-1, Ly 2 and LFA-1, but negative for L3T4 and asialo GM1. The staining profile of the cells with each antibody indicated that the CTL clones consisted of just one cell type. Monoclonal anti-Ly 2.2 and anti-LAA (lymphokine-activated cell-associated antigen) antibodies inhibited cytolysis of CTL and hyperactivated CTL clones against TNP-modified spleen cells, but failed to inhibit the anomalous killing of the hyperactivated CTL. The cold target competition test suggested the degeneracy of antigen specificity. The present study demonstrated that the CTL clone acquired a new specificity for tumor target cells upon stimulation with a high dose of rIL-2.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000943 Antigens, Differentiation Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation. Differentiation Antigen,Differentiation Antigens,Differentiation Antigens, Hairy Cell Leukemia,Differentiation Marker,Differentiation Markers,Leu Antigen,Leu Antigens,Marker Antigen,Marker Antigens,Markers, Differentiation,Antigen, Differentiation,Antigen, Leu,Antigen, Marker,Antigens, Leu,Antigens, Marker,Marker, Differentiation

Related Publications

T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Human alloreactive CTL clones: loss and reacquisition of specific cytolytic activity can be regulated by "recombinant" interleukin 2.
January 1985, Journal of immunology (Baltimore, Md. : 1950),
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Activation of virus specific CTL clones: antigen-dependent regulation of interleukin 2 receptor expression.
February 1985, Journal of immunology (Baltimore, Md. : 1950),
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
May 2011, Cancer science,
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
September 2011, Cancer immunology, immunotherapy : CII,
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells.
February 2003, Journal of immunology (Baltimore, Md. : 1950),
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Induction of HLA-specific CTL to nonimmunogenic, heat-inactivated lymphocytes by interleukin 2.
November 1990, Transplantation,
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Induction of peptide-specific CD8+ CTL clones in beta 2-microglobulin-deficient mice.
January 1995, Journal of immunology (Baltimore, Md. : 1950),
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Differential regulation of interleukin 2 (IL-2) receptor expression on antigen-specific human T cell clones by IL-2.
January 1988, Immunology letters,
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Characterization of CTL Clones Specific for Single Antigen, H60 Minor Histocompatibility Antigen.
April 2011, Immune network,
T Moriyama, and G Suzuki, and I Nakao, and S Aizawa, and K Okumura, and T Nishimura, and F Takaku
Induction of cytolytic cells by pure recombinant human interleukin 2.
November 1984, European journal of immunology,
Copied contents to your clipboard!